radiomics.bio

Radiomics.bio is a next generation technology to improve drug development and patient treatment plans paving the way to #ultraprecisionmedecine. Generating more impactful information through our #AI and 3D #medicalimaging technology, learn how Radiomics.bio can be beneficial to the patients and your #clinicaltrials. Make sure to stay up to date on our latest advances on our website! https://radiomics.bio/

Today at #SITC24, CEO Wim Vos and Business Manger Hanif Gabrani-Juma-Gabrani Juma will present poster #131 Baseline and early follow-up Radiomics Biomarkers for Tumour Growth in Uveal Melanoma Patients Treated with Roginolisib (IOA-244) conveying the ability of radiomics to identify induvial tumour growth profiles While immunotherapies pose as a powerful solution in cancer treatment many challenges are encountered in drug development trajectories leading to poor patient response. Between 20-40% respond positively to immunotherapies, so how can radiomics address this issue? Through quantitative image analysis, comprehensive tumour burden analysis and advances statistics, radiomics poses a viable antidote to the challenges in immunotherapy, notably its ability to predict patient response and quantify response   To find out more, meet Wim and Hanif at SITC this week!

Today at #SITC24, CEO Wim Vos and Business Manager Hanif Gabrani-Juma-Gabrani Juma will present poster #131 Baseline and early follow-up Radiomics Biomarkers for Tumour Growth in Uveal Melanoma Patients Treated with Roginolisib (IOA-244) conveying the ability of radiomics to identify induvial tumour growth profiles. While immunotherapies pose as a powerful solution in cancer treatment many challenges are encountered in drug development trajectories leading to poor patient response. Between 20-40% respond positively to immunotherapies, so how can radiomics address this issue? Through quantitative image analysis, comprehensive tumour burden analysis and advances statistics, radiomics poses a viable antidote to the challenges in immunotherapy, notably its ability to predict patient response and quantify response.   To find out more, meet Wim and Hanif at #SITC24 this week!

Congratulations to Dr. Jörg Stein who has been named as one of the seven finalists for the Business Angel of the Year award by Business Angels Deutschland. This is a well-deserved recognition of Jörg’s contributions! We are very proud to have Jörg as an angel investor and a member of our board. Jörg has contributed to the success of countless business endeavors and has been a key driver behind the scenes at radiomics.bio. It is now our pleasure to support him from the sidelines and we wish him the best as he advances as a finalist! 

Today marks the end of liver cancer awareness month, while the incidence rate of liver cancer is rapidly growing, improvements are needed to increase the effectiveness of treatment. Throughout this month we reflected on how we can protect ourselves as potential patients and how we can improve treatment plans for those who have been affected.  Over the last decade significant advances have been made that have vastly improved how liver cancer is treated, notably the advances that have been made possible via imaging. Why is this so important? Biopsies are an invasive procedure that only provides information pertaining to the site from which the biopsy was made.  Through imaging, radiomics provides vital information related to the tumour including genetic expression to get a better understanding of tumour morphology and thereby plan effective therapeutic plans and drug development.  #LiverCancerAwarenessMonth #LiverCancer

🌍 Nous sommes heureux d'avoir accueilli à Liège, vendredi passé, M. Aoyama, Économiste en Chef et expert en investissements life sciences à la Development Bank of Japan Inc., pour lui faire découvrir les spécificités de l’écosystème wallon. Nous avons échangé sur ses forces et partagé nos expériences en matière d'amélioration de nos écosystèmes respectifs. Ces riches échanges ont inclus des présentations de Noshaq (Leen LIMBOURG), Université de Liège (Michel Moutschen), ULiège - RISE (Annelise Ngendakumana), L'Orange 5G Lab (Renaud Falise), radiomics.bio (Wim Vos), QUALIblood (Julie Winand), La Grand Poste (Romina Pace) et LégiaPark (Aurore Duijsens). 🚀 Bridge to Health (B2H) est fière de remplir ses missions : promouvoir, connecter et développer. 💪 Un grand merci à tous les intervenants pour leur implication ! 🌍 We were pleased to welcome Mr. Aoyama, Chief Economist and expert in life sciences investments at the Development Bank of Japan Inc., to Liège last Friday to introduce him to the specificities of the Walloon ecosystem. We discussed its strengths and shared our experiences in improving our respective ecosystems. These fruitful discussions included presentations from Noshaq (Leen LIMBOURG), Université de Liège (Michel Moutschen), ULiège - RISE (Annelise Ngendakumana), Orange 5G Lab (Renaud Falise), radiomics.bio (Wim Vos), QUALIblood (Julie Winand), La Grand Poste (Romina Pace) et LégiaPark (Aurore Duijsens). 🚀 Bridge to Health (B2H) is proud to fulfill its missions: promote, connect, and develop. 💪 A big thank you to all the speakers for their commitment!

Join CEO, Wim Vos and Business Manager, Hanif Gabrani-Juma at the annual Society of Immunotherapy for Cancer conference from November 6th-10th.     Bringing together thousands of attendees from industry, academia and the clinic, SITC aims to to improve cancer treatment through the development and application of cancer immunology and immunotherapy through interaction, integration and innovation. Along with SITC and other attendees we look forward to seeing how we can advance the science and application of cancer immunotherapy worldwide.   #SITC24 

Nobel Prize Alert: Celebrating the Pioneers of Neural Networks!  The 2024 Nobel Prize in Physics has crowned two trailblazers who unlocked the power of neural networks, sparking a revolution in how we understand and predict the world around us. Their work laid the groundwork for some of the most exciting advances in radiology today.  Flashback to 2012: Radiomics.bio published the first radiomics paper, opening the floodgates for using radiological features to predict disease outcomes. Fast forward to 2016, and AI-radiology companies were springing up left and right, thanks to these neural network foundations.  Today, at Radiomics.bio, we use neural networks and other deep and machine learning approaches to predict biology, disease characteristics, lesion-level response, and patient-level response. Our mission? To push the boundaries of precision imaging and patient care, and better understand drugs in early stages of clinical development!  We look forward to seeing how machine learning and artificial intelligence will continue to benefit society. For now, we’d like to thank John J. Hopfield and Geoffrey E. Hinton for their revolutionary discoveries.  To learn more about the development of machine learning, click here: https://lnkd.in/dyUfXAtg

The promising results from Kazia Therapeutics Limited’s trial lay the groundwork for improving ovarian cancer treatment. We are very proud of Medical Director, Andrea Corsi, and Project Manager, Nathan Tsoutzidis for being part of this project which may greatly improve how ovarian cancer is treated. At Radiomics.bio, we quantified volumetric disease response from screening to week 8 of treatment and identified radiomic features preceding the volumetric, such as the compactness, homogeneity and density changes of lesions. The quantification of individual lesion feature changes supports biological hypothesis and provides additional insights driving clinical trial decision making. We now look forward to advancing to Phase II and seeing how impact Kazia Therapeutics will continue to make in the treatment of ovarian cancer.  

Ce vendredi, le LégiaPark a eu l’immense plaisir de rencontrer une vingtaine de conseillers économiques et commerciaux (CEC), conseillers scientifiques et académiques et délégués Wallonie Bruxelles International à l’occasion des Journées diplomatiques organisées par l’ Agence wallonne à l'exportation et aux investissements 🤝👩🏫 Au programme de cet échange : •⁠ ⁠une présentation du LegiaPark par notre CEO, Aurore Duijsens •⁠ ⁠Une visite de nos infrastructures  •⁠ ⁠Pitch session de trois de nos locataires représentés par Hugues Wallemacq - EXO Biologics , Jeroen Cant - Radiomics.bio et Dimitri Woronoff - White Raven. •⁠ ⁠Networking autour d’un walking dinner Merci à Marielle Germis et Noura B. pour l’organisation ce beau moment d’échanges. --- Last Friday, LégiaPark had the great pleasure of meeting some twenty Economic and Commercial Advisors (CEC), Scientific and Academic Advisors and Wallonie Bruxelles International Delegates at the Diplomatic Days organized by the Agence wallonne à l'exportation et aux investissements 🤝👩🏫 The program included - a presentation of LegiaPark by our CEO, Aurore Duijsens - A tour of our facilities - Pitch session with three of our tenants represented by Hugues Wallemacq - EXO Biologics , Jeroen Cant - Radiomics.bio and Dimitri Woronoff - White Raven. - Networking over a walking dinner Many thanks to Marielle Germis and Noura B. for organizing this wonderful opportunity to exchange ideas.